Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs.
Nuformix is a London-based pharmaceutical firm targeting fibrosis and oncology. The company is working on developing drugs, such as NXP002, a potential treatment for idiopathic pulmonary, and has a cancer programme named NXP004, focused on the treatment for advanced ovarian cancer.
In the six months to September 30, pretax loss narrowed slightly to £423,677 from £449,022 a year prior. Revenue fell to nothing from an insignificant £50,000, as its products remain in development.
Executive Director Dan Gooding said: ‘Our pre-clinical efforts to date demonstrate that inhaled treatment of idiopathic pulmonary fibrosis and related fibrotic lung diseases via NXP002 is a viable concept, a concept that it is becoming increasingly validated by clinical data emerging from the public domain.’
Looking ahead, Nuformix said: ‘The company to continues to advance and exploit the current assets within the portfolio through the research & development and business development activities.’
It added: ‘The strategy of the group is to continue to increase the value of its existing assets while maintaining tight control of costs, including conducting business development/licensing activities using a structured and data-driven approach, with the goal of seeking global licensing deals.’
Nuformix shares were 12% lower at 0.32 pence each on Tuesday afternoon in London. The stock i s down 77% over the past 12 months.
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.